Pfizer Stock (PFE) Opinions on Earnings Results and Pipeline Updates

Pfizer (PFE) has initiated a review with the European Medicines Agency (EMA) for its Lyme disease vaccine, according to the company. This development could impact investors' views on Pfizer's pipeline and potential market opportunities in Lyme disease prevention.

Zoetis (ZTS) reported flat Q2 revenue of $2.47B, missing estimates, and lowered full-year guidance. Supernus Pharmaceuticals (SUPN) reported 27.7% revenue growth to $211.3M, beating estimates. Eli Lilly (LLY) reported 47.7% revenue growth to $22.97B, significantly beating estimates. All three stocks have risen since reporting.

Pfizer (PFE) and Johnson & Johnson (JNJ) face patent expirations. Pfizer's non-COVID revenue grew 5% in Q2 2026, with key drugs like Padcev and Vyndaqel driving expansion. JNJ's Innovative Medicine sales rose 6.8% operationally, led by Tremfya's 72.5% growth. JNJ raised its 2026 sales and EPS guidance, highlighting diversification.

Pfizer (NYSE:PFE) reported a 1% operational revenue increase in Q2 2026 to $15.0B, with non-COVID products growing 5%. Management raised full-year guidance. Newer products like Padcev and Vyndaqel showed growth, but patent expirations pose risks. Cost savings targets were expanded to $5.7B by 2026 and $6.7B by 2029. Revenue growth was modest, and GAAP pre-tax loss was reported due to various charges.

Pfizer (PFE) and Gilead (GILD) are compared on growth prospects. Pfizer's non-COVID revenue grew 5%, with key drugs like Padcev and Vyndaqel showing gains. Gilead's non-Veklury sales rose 10%, driven by HIV and oncology drugs. Both companies adjusted 2026 forecasts, with Gilead raising its outlook.

Pfizer (PFE) shares dropped 3% on Wednesday despite FDA approval for Ibrance in a new breast cancer treatment, as investors reacted to a failed lung cancer trial. Ibrance's approval is based on a trial showing a 24% reduction in cancer progression or death. PFE stock has fallen 5% year-to-date.